First Phase II trial with Genentech's Met inhibitor in NSCLC suggests potential biomarker
This article was originally published in Scrip
Executive Summary
Genentech’s (Roche) MetMAb, a monoclonal antibody that blocks activation of the Met receptor, showed some promise in its first Phase II trial started in April 2009 which evaluated it in combination with Roche’s small molecule EGFR inhibitor Tarceva (erlotinib) in previously treated non-small cell lung cancer (NSCLC).